Gossamer Bio FY2025 EPS Estimate Lifted by Cantor Fitzgerald

Key Points

• Analysts at Cantor Fitzgerald have raised their FY2025 earnings per share estimate for Gossamer Bio to ($0.63), up from a previous projection of ($0.71).
• Gossamer Bio's shares have shown a recent decline of 0.5%, with a current market price of $2.16.
• Institutional investors hold 81.23% of Gossamer Bio's stock, indicating significant interest from larger investment firms.

Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Stock analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for shares of Gossamer Bio in a research report issued to clients and investors on Monday, August 4th. Cantor Fitzgerald analyst O. Brayer now forecasts that the company will post earnings of ($0.63) per share for the year, up from their prior estimate of ($0.71). The consensus estimate for Gossamer Bio's current full-year earnings is ($0.28) per share. Cantor Fitzgerald also issued estimates for Gossamer Bio's FY2026 earnings at ($0.24) EPS.

A number of other research firms also recently weighed in on GOSS. Scotiabank assumed coverage on Gossamer Bio in a research report on Monday, July 14th. They issued a "sector outperform" rating and a $11.00 target price for the company. Wedbush upped their price objective on Gossamer Bio from $4.00 to $5.00 and gave the company an "outperform" rating in a report on Wednesday. Finally, The Goldman Sachs Group lifted their target price on Gossamer Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Friday, May 16th.

Gossamer Bio Price Performance

Shares of GOSS stock traded up $0.02 during midday trading on Wednesday, reaching $1.76. 3,069,886 shares of the company were exchanged, compared to its average volume of 3,500,859. The company's 50 day moving average price is $1.51 and its two-hundred day moving average price is $1.24. The company has a debt-to-equity ratio of 6.70, a quick ratio of 5.71 and a current ratio of 4.40. The company has a market cap of $400.19 million, a P/E ratio of -2.84 and a beta of 1.96. Gossamer Bio has a 12 month low of $0.66 and a 12 month high of $2.23.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.01. The business had revenue of $11.49 million during the quarter, compared to the consensus estimate of $4.12 million. Gossamer Bio had a negative net margin of 344.81% and a negative return on equity of 1,774.72%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its stake in shares of Gossamer Bio by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company's stock worth $2,037,000 after acquiring an additional 38,084 shares in the last quarter. Silverarc Capital Management LLC lifted its holdings in shares of Gossamer Bio by 9.3% during the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company's stock valued at $5,583,000 after purchasing an additional 526,495 shares during the last quarter. Opti Capital Management LP acquired a new position in shares of Gossamer Bio in the 4th quarter valued at $165,000. Allostery Investments LP purchased a new position in Gossamer Bio in the 4th quarter worth about $555,000. Finally, Alyeska Investment Group L.P. raised its holdings in Gossamer Bio by 52.7% during the 4th quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company's stock worth $7,968,000 after buying an additional 3,041,058 shares during the period. Institutional investors and hedge funds own 81.23% of the company's stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.